Regulatory Filings • Mar 1, 2023
Regulatory Filings
Open in ViewerOpens in native device viewer
VALNEVA SE Campus Bio-Ouest | 6, Rue Alain Bombard 44800 Saint-Herblain, France
Saint-Herblain (France), March 1, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at the Cowen 43rd Annual Healthcare Conference, to take place in-person March 6 - 8, 2023 in Boston, Massachusetts.
Key topics to be covered by Chief Executive Officer Thomas Lingelbach and Chief Financial Officer Peter Bühler include the Company's late-stage vaccine candidates targeting chikungunya (VLA1553) and Lyme disease (VLA15).
The presentation will take place on Tuesday, March 7, 2022, at 10:30am ET and will be accessible live via the following link, https://wsw.com/webcast/cowen132/valn/2015538. A replay of the webcast will be available following the live event in the "Investors" section of the Valneva website at www.valneva.com.
To request a meeting at the event, please contact your representative at Cowen.
Cowen's 43rd Annual Health Care Conference will take place March 6 - 8, 2023, at the Boston Marriott Copley Place in Boston, MA. The conference incorporates presentations, fireside chats and innovative panel discussions hosted by members of the Cowen research team that focus on various aspects of the health care industry.
Valneva is a specialty vaccine company focused on the development, manufacturing and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company takes a highly specialized and targeted approach to vaccine development and then applies its deep understanding of vaccine science to develop prophylactic vaccines addressing these diseases. Valneva has leveraged its expertise and capabilities both to commercialize three vaccines and to rapidly advance a broad range of vaccine candidates into the clinic, including candidates against the chikungunya virus and Lyme disease.
Laetitia Bachelot-Fontaine VP, Global Communications and European Investor Relations M +33 (0)6 4516 7099 [email protected]
Joshua Drumm, Ph.D. VP, Global Investor Relations M +001 917 815 4520 [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.